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Abstract
Background: Community-acquired pneumonia (CAP) is one of the most common infections, especially in the elderly
(≥65 years). The aim of this study was to quantify hospitalization costs for CAP in different age groups and in patients
with different CAP risk profiles. Secondary objectives were to assess disease severity differences between placebo and
vaccine receiving participants and identify cost driving factors of CAP in hospitalized elderly in the Netherlands.
Methods: This prospective cohort study of hospitalized CAP patients was executed in parallel to the Community
Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Within the CAPiTA, a cohort of 84,496 subjects aged ≥65,
all suspected CAP-episodes presenting in one of the 58 participating hospitals between September 2008 and August
2013 were included. CAP was diagnosed on clinical and radiographical criteria. Invasive pneumococcal disease (IPD)
and non-IPD-CAP episodes, regardless of the causing pathogen, were evaluated separately. Costs were calculated by
multiplying recorded healthcare resources with Dutch unit cost prices for the year 2012. Multivariate regression analysis
was performed to identify cost drivers.
Results: In the sentinel hospitals 3225 suspected CAP and IPD episodes were included, of which 1933 were
radiographically confirmed by chest X-ray. Analyses were conducted on confirmed CAP episodes only. Overall mean
length of hospital stay was 12.1 days, the in-hospital mortality rate was 11.26 %, and mean costs were €8301 (95 % CI:
€7760–€8999). When stratified in age-categories 65–74, 75–84 and ≥85, mean hospitalization costs were €8674, €8770
and €6197, respectively (p = 0.649). IPD-CAP and non-IPD-CAP mean hospitalization costs were €13,611 and €8081,
respectively. Higher CURB-65 score and individuals at medium risk for developing pneumococcal disease were
significantly associated with higher costs. Being male, lower age, previous admissions, lower risk, lower urbanity and
higher socio-economic status were associated with lower costs.
Conclusions: Mean hospitalization costs of a CAP subject were €8301 and higher for IPD-CAP compared to non-IPD-CAP
cases. Medium risk patients and higher CURB-65 scores were identified as cost driving factors.
Keywords: Community-acquired pneumonia, Costing study, Elderly, Hospitalization, Invasive pneumococcal disease,
Risk-groups
Abbreviations: CAP, Community-acquired pneumonia; CAPiTA, Community Acquired Pneumonia Immunization Trial in
Adults; CI, Confidence interval; DBC, Diagnosis Related Groups (in Dutch: Diagnose Behandel Combinatie); Etio-
CAP, Etiology and prognosis of community-acquired pneumonia study; GP, General practice; ICD, International
Classification of Diseases; ICU, Intensive care unit; IPD, Invasive pneumococcal disease; IPD-CAP, Community-acquired
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Background
Community-acquired pneumonia (CAP) is one of the
most common infectious diseases in the world [1–4]. In
Europe, the incidence of all-cause CAP (hospitalized and
outpatient) in the elderly population (≥65 years) is
estimated at 14 per 1000 person years [5, 6]. Approxi-
mately 56 % (equal to €5.7 billion) of CAPs economic
burden in Europe is ascribed to hospitalization expenses
[7]. The other costs can be attributed to outpatient care,
loss of workdays and drug expenses. Increasing CAP
incidence due to growth of the elderly population in the
upcoming years [8–11], more severe episodes due to
increasing comorbidity within the aging population [12],
and limited economic resources demand for new
preventive measures [13]. In Western countries like the
Netherlands, new healthcare interventions will be evalu-
ated for their costs and effects and detailed cost esti-
mates are indispensable in this process. However, most
larger studies describing CAP costs were conducted
retrospectively and based on insurance claims with lim-
ited clinical information [4, 14–19]. The few prospective
studies on CAP hospitalization costs covered relative
small cohorts only [20–22].
The Community Acquired Pneumonia Immunization
Trial in Adults trial (CAPiTA), a nation-wide study
assessing the efficacy of the 13-valent pneumococcal vac-
cine (PCV13) in the elderly, created a unique opportunity
for quantifying hospitalization costs of CAP [23, 24]. A
parallel study was designed to estimate costs for hospital-
ized CAP patients, including patients with and without
invasive pneumococcal disease (IPD), stratified by age-
and risk-groups for developing pneumococcal infections
and by outcome (i.e. mortality). Secondary objectives were
to analyze disease severity differences between PCV13 and




The etiology and prognosis of community-acquired
pneumonia (Etio-CAP) study is a prospective cohort
study conducted in parallel to CAPiTA [23, 24]. In this
double blind randomized clinical vaccination trial in the
Netherlands, the efficacy of PCV13 in adults was
evaluated by vaccinating 84,496 subjects of ≥65 years of
age with either placebo or PCV13 with an average
follow-up period of 3.97 years [24]. Detailed information,
in- and exclusion criteria and outcome measures have
been previously described [23, 24]. Follow-up was
organized in 59 sentinel centers (58 hospitals and 1
outpatient clinic) between September 2008 and August
2013, where the 58 hospitals participated in the Etio-
CAP study. When a CAPiTA-participant was registered to
one of these hospitals with a suspicion of pneumonia,
regardless of the causing pathogen, clinical data were col-
lected according to the CAPiTA protocol. When admitted,
additional data, like use of resources and complications,
were collected as part of the Etio-CAP-study.
Definitions
CAP was defined, regardless of the causing pathogen, as
the presence of two or more clinical signs of pneumonia
together with a chest x-ray consistent with pneumonia
[23]. IPD was defined as Streptococcus pneumoniae
cultured from a sterile site (e.g. blood). The analysis was
conducted for three groups: ‘total CAP’ (i.e. all con-
firmed CAP cases), non-IPD-CAP (i.e. confirmed CAP
cases, no IPD) and ‘IPD-CAP’ (i.e. cases with confirmed
CAP and IPD). Subjects with IPD without CAP were not
included in the analyses.
Admissions within 30 days post-discharge of a sus-
pected CAP hospitalization episode were labeled as a re-
admission and treated as a continuation of the previous
admission with regard to a) diagnosis (CAP or IPD) and
b) costs (i.e. resources used in first and following admis-
sions, and associated costs were added up).
The study was approved by the Central Committee on
Research Involving Human Subjects (CCMO11.0810/
TV/NL23014) as a sub-study of the CAPiTA-trial.
Therefore no separate informed consent was required
for the Etio-CAP study.
Data collection
Data collected included length of stay (LOS) and intensive
care unit (ICU) admission, comorbidities at moment of
admission (see Additional file 1: Table S1), date of
symptom onset and date of symptom relieve. Based on
the presence of comorbidities, subjects were stratified
into high (i.e. immunocompromised patients), medium
(i.e. presence of other chronic conditions) and low
risk for pneumococcal infections (Additional file 1:
Table S1).
Data included for the Etio-CAP-study concerned:
mortality (with minimum follow-up of 6 months after
hospital admission, i.e. confirmation of vital status by
the GP of the participant), laboratory results, number of
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hospital admissions 1 year prior to index CAP
hospitalization episode, diagnostic and therapeutic inter-
ventions for both pneumonia and its complications, add-
itional “waiting days” in the hospital (i.e. before home
care could be organized), and location of discharge (own
home or nursing home). Pneumonia severity was
assessed using the Pneumonia severity index (PSI), as
described by Fine et al. [25], and CURB-65 [26]. PSI
score was categorized into low (score 1 and 2), medium
(score 3 and 4) and high (score 5). Based on postal
codes, information on socioeconomic status (continues
variable from low to high, scores ranging from -5.5 to 3,
with lower scores reflecting lower socio-economic
status) and urbanity of neighborhood (from high to low;
score 1, 2, 3, 4 and 5) was obtained from Statistics
Netherlands and referred to the situation in 2010 [27].
Costs
Hospitalization costs were calculated by multiplying
recorded units of healthcare resources used with corre-
sponding unit prices (see Additional file 1: Table S2)
[28]. Unit costs were either taken from the Dutch
manual for healthcare costing research [28, 29] or were
calculated from a unit price medium of different hospital
price lists available. All costs were expressed for the year
2012, and if necessary, updated using Dutch consumer
price indices [30].
Statistical Analysis
Data were analyzed using IBM SPSS Statistics for
Windows, Version 20.0. The one-way ANOVA test,
Mann-Whitney U-test and the Kruskal-Wallis test were
used to compare quantitative variables and the Chi-
square test was used for categorical variables. Intubation
days at the ICU were recorded in a dichotome (yes or
no) and a quantitative way (e.g. number of days of intub-
ation). There were no missing data with the exception of
number of intubated ICU days (0.6 %) and number of
previous admissions (0.2 %). Missing data were impu-
tated using multiple imputation. A stepwise multiple
regression model was used to identify cost drivers with
log-transformed hospitalization costs as a dependent
variable. Explanatory variables were gender, age, previous
admission (categorized as: none, one, two, three or more
admissions), smoking status (non-smoker, previous
smoker, current smoker), risk-level, socioeconomic
status and urbanity, and CURB-65. The latter was used
instead of PSI scoring, because of overlapping definitions
between PSI and risk levels as both are estimated using
comorbidity information. The 95 % confidence interval
(CI) was determined using bootstrapping with 1000
iterations. A p-value of <0.05 was considered significant.
Results
Study participants
There were 3225 registered suspected CAP episodes, of
which 138 were not hospitalized. Of these suspected and
hospitalized CAPs 1154 cases were not confirmed as
CAP (i.e. no positive chest X-rays and/or <2 clinical
signs of pneumonia) and consequently excluded from
the analysis (Fig. 1). Of the remaining 1933 confirmed
CAP admissions, 148 were readmissions, yielding 1785
episodes for analysis. Of these, 74 had IPD-CAP and
1714 had non-IPD-CAP) (Fig. 1).
Fig. 1 Flowchart of the study. Legend: *Including 3 readmissions; **Including 145 readmissions. Abbreviations: CAP: community-acquired
pneumonia; IPD-CAP: invasive pneumococcal disease
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The majority (73 %) of CAP patients were male, and the
mean length of hospitalization was 12.1 days (95 %
CI: 2–42 days) consisting of 92 % ward days and 8 %
ICU days (Table 1). The 30-day mortality rate of low,
medium and high risk-groups was 4, 10.4 and 29.1 %,
respectively. Compared to non-IPD-CAP cases, IPD-
CAP cases had a longer average duration of stay in
hospital (p = 0.028) and in ICU (p = 0.022) (Table 1).
Costs
The mean hospitalization cost for all CAP subjects was
€8301 (Median: €4809, 95 % CI: €7760–€8999) (Table 2
and Additional file 1: Table S3). General ward nursing costs
accounted for 63 % of total hospitalization costs and ICU
nursing for 29 %. When stratified by age groups 65–74,
75–84 and ≥85 years, mean hospitalization costs were
€8674, €8770 and €6197, respectively (p = 0.649). The
mean hospitalization costs per IPD-CAP case were sig-
nificantly higher than for non-IPD-CAP cases (€13,611
versus €8081, p = 0.025).
The mean hospitalization cost for survivors and non-
survivors in the total CAP cohort was €7638 and
€13,526, respectively (p = 0.30) (Figs. 2 and 3). ICU costs
of survivors were lower (p < 0.001) and ward costs were
higher (p < 0.001) compared to non-survivors.
Comparison between subjects who received PCV13
(n = 861) and placebo (n = 924) revealed no differences
in LOS (12.03 versus 12.17 days, p = 0.919), PSI category
(2.13 versus 2.09, p = 0.368) and mean hospitalization
Table 1 Baseline characteristics of study population
Total CAP IPD-CAP non-IPD-CAP p-value
Admissiona, n 1785 71 1714
Age in years, mean (SD) 77.4 (6.6) 76 (5.5) 77.5 (6.7)
Male, n (%) 1307 (73.2) 43 (60.6) 1264 (73.7) *
ReceivedPCV13, n (%) 861 (48.2) 24 (33.8) 837 (48.8) *
Risk group for developing pneumococcal disease, n (%)
• Low 248 (13.9) 18 (25.4) 230 (13.4)
• Medium 1207 (67.6) 47 (66.2) 1160 (67.7)
• High 330 (18.5) 6 (8.5) 324 (18.9)
Length of stay in days, mean (95 % CI) 12.1 (11.6–12.6) 15.3 (12.3–18.9) 12.0 (11.5–12.4) *
• Ward days, mean (95 % CI) 11.1 (10.7–11.6) 13.0 (10.3–15.8) 11.1 (10.6–11.5)
• ICU days, mean (95 % CI) 1.0 (0.8–1.2) 2.4 (0.9–4.2) 0.9 (0.7–1.1) *
• Intubationdays, mean (95 % CI) 0.4 (0.3–0.6) 1.1 (0.3–2.2) 0.4 (0.3–0.6) *
Illness duration in daysb, mean (95 % CI) 16.9 (16.3–17.5)c 19.8 (16.1–24.1) 16.7 (16.1–17.4)c
Days between onset and hospital admission, mean (95 % CI) 4.9 (4.6–5.2)d 4.3 (2.7–6.8) 4.9 (4.6–5.3)d
Pneumococcal severity index (PSI), n (%)
• I-II 126 (7.1) 5 (7.0) 121 (7.1)
• III-IV 1327 (74.3) 48 (67.6) 1279 (74.6)
• V 332 (18.6) 18 (25.4) 314 (18.3)
In-hospitalmortality, n (%) 201 (11.3) 11 (15.5) 190 (11.1)
30-day mortality, n (%) 235 (13.2)e 11 (15.5) 224 (13.1)e
60-day mortality, n (%) 300 (16.8)e 12 (16.9) 288 (16.8)e
6-months mortality, n (%) 444 (24.9)e 18 (25.4) 426 (24.9)e
Location of discharge, n (%) 1584 (88.7) 60 (84.5) 1524 (88.9)
• Home 1371 (86.6) 51 (85.0) 1320 (86.6)
• Nursing home 160 (10.1) 8 (13.3) 152 (10)
• Others 53 (3.3) 1 (1.7) 52 (3.4)
*Statistically significant difference between non-IPD-CAP and IPD-CAP
aAdmissions within 30 days post-discharge of a suspected CAP hospitalization episode were labeled as a readmission and analyzed as a continuation of the
previous admission
bNumber of days from onset to hospital discharge
c11 with missing data
d9 with missing data
e2 with missing data
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costs (€8115 versus €8475, p = 0.835). Furthermore, LOS,
PSI category and costs were similar for subjects with IPD-
CAP and non-IPD-CAP.
Cost drivers
A high CURB-65 score and medium risk profile for
pneumococcal CAP were associated with higher
hospitalization cost (Table 3). Male gender, increasing age,
one or more previous admissions in the past year, low risk
profile for pneumococcal CAP, lower urbanity and higher
socio-economic status were associated with lower costs.
Discussion
Among those who participated in the CAPiTA-study,
the mean costs of hospitalization for CAP were €8301.
Costs for a hospitalized CAP episode with IPD were
€13,611, or 168 % of the mean costs for a non-IPD-CAP
episode (i.e. €8081). A high clinical severity of disease at
the time of hospitalization and having medium risk
profile for pneumococcal disease were identified as inde-
pendent drivers of high costs, whereas male gender, in-
creasing age, previous admission(s) in the past year, low
risk profile for pneumococcal CAP, lower urbanity and
higher socio-economic status were associated with lower
overall costs. Vaccination status was not associated with
clinical severity of CAP or costs of hospitalization.
Quantification of costs associated with CAP are
usually based on retrospective studies using national
insurance claims databases. In a previous retrospective
study in Netherlands by Spoorenberg et al. [20], median
costs based on ICD recordings were estimated at €3899.
In the current study median costs were €4809, and the
difference could be explained by the younger cohort in
the Spoorenberg et al. study (mean age 63.4 versus 77.4)
potentially leading to a shorter LOS (8.5 versus 12 days)
and a lower case-fatality rate (30-day mortality: 5.1
versus 13.1 %). Furthermore, in the current study, non-
survivor costs were €13,526 and appeared to be 177 % of
the hospitalization costs of survivors (i.e. €7638). Also,
Spoorenberg et al. did not consider the additional costs
of readmissions and included patients of only two
general hospitals in the Netherlands, as compared to 58
hospitals, of which seven are tertiary care centers, were
included in the current study. Indeed, the proportion of
patients needing ICU admission was 21.2 % in tertiary
care (24/113) and 12.1 % in general hospitals (202/1672).
Another nationwide ICD-based cost analysis by
Rozenbaum et al. [19] reported medium costs of CAP of
€6060 and €5937 in those 65–74 and 75–84 years of age,
respectively, which is also lower than the medium costs
for these age cohorts in the current study (€8674 and
€8770, respectively). The study by Rozenbaum et al. was
based on reimbursement of hospital expenses, as
regulated by Diagnosis Related Groups (in Dutch:
Diagnose BehandelCombinatie or DBC). By selecting
solely DBCs related to pneumonia, other costs (e.g.
treatment of complications) were not considered,
possibly explaining the lower costs. Also readmissions
were not taken into account, resulting in shorter length
of stay in the 65–74 and 75–84 age cohorts (7.7 versus
12.4 and 8.1 versus 12.3, respectively). Furthermore, the
use of ICD-coding in both Dutch studies [19, 20] may
have caused important misclassification. In another
Dutch study across seven Dutch hospitals, the sensitivity
of ICD-coding was estimated at 79.5 % [31]. The current
prospective study with 1933 patients with confirmed
CAP based on standardized diagnostic criteria may,
therefore, be more precise and generalizable than
previous studies [16, 19–22].
Table 2 Hospitalization costs of CAP and IPD-CAP subjects





N Mean 95 % Confidence
Interval
Lower Upper
Total CAP All 1,785 8,301 7,760 8,999
65-74 All 678 8,674 7,841 9,641
Low 87 8,418 5,870 11,696
Medium 445 9,118 7,921 10,407
High 146 7,472 6,163 9,248
75–84 All 807 8,770 7,748 9,847
Low 73 10,387 7,222 14,516
Medium 574 8,270 7187 9,550
High 160 9,828 7,345 12,811
≥85 All 300 6,197 5,677 6,764
Low 42 6,042 4,978 7,188
Medium 227 6,198 5,606 6,832
High 31 6,401 5,039 8,238
IPD-CAP All 71 13,611 8,612 20,434
65–74 All 31 11,635 6,996 17,982
Low 8 16,185 5,336 34,137
Medium 20 10,615 5,831 17,142
High 3 6,299 3,815 8,960
75–84 All 34 16,496 7,650 30,360
Low 6 18,837 3,880 41,063
Medium 25 16,903 6,182 35,483
High 3 8,416 1,268 21,697
≥85 All 6 7,478 3,456 12,416
Low 2 7,440 3,860 11,020
Medium 4 7,497 2,238 16,577
High 0 - - -
Due to minimal differences between total CAP and non-IPD-CAP cohorts costs,
the latter are presented in Additional file 1: Table S3
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Different settings and healthcare systems makes a com-
parison between countries nearly impossible at the level of
cost estimates [32]. Length of Stay (LOS) has been identi-
fied as a major contributor to healthcare resource
utilization. We found a mean of 12 days which is within the
range of other European studies, [21, 22, 33–40], ranging
from 8 up to 13.2 days.
There are also limitations of this study that need to be
addressed. An exclusion criterion for the CAPiTA-trial
was the presence of immunodeficiency (i.e. individuals at
high risk for developing pneumococcal infections),
except for patients with asplenia. However, there were
330 (18.5 %) patients with CAP that had developed
immune deficiencies after enrollment in the CAPITA-
trial. Hospital costs might be slightly underestimated as
we did not have exact information on the percentage of
patients that received in-hospital rehabilitation services,
or because some diagnostic or therapeutic procedures,
such as incidental pleural punctures, may not have been
reported. Additionally, in the current cohort 10.1 % of
the survivors were discharged to a nursing home or
rehabilitation center. As information on the total length
of stay in nursing home or rehabilitation center was lack-
ing, we could not add these costs to our cost estimates.
Conclusion
The current study showed variability in hospitalization
cost between different ages, disease severities and
survival status. The eldest group experienced high mor-
tality and shorter ICU admission. Mean hospitalization
Fig. 2 Mean CAP-related hospitalization cost for the total CAP cohort, survivors and deceased persons stratified by age. Error-bars depicting the
95 % confidence interval of the mean. Results obtained using boostrapping
Fig. 3 Mean CAP-related hospitalization cost for the total CAP cohort, survivors and deceased persons stratified by severity (i.e. PSI score).
Error-bars depicting the 95 % confidence interval of the mean. Results obtained using boostrapping. Abbreviations: CAP:
community-acquired pneumonia; PSI: Pneumococcal Severity Index
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cost for a CAP subject was €8301. Costs are significantly
higher for IPD-CAP than for non-IPD-CAP cases. With
an aging population and a rising life expectancy the
disease and economic burden may further increase in
the near future.
Additional files
Additional file 1: Table S1. Comorbidities considered at increased risk
for developing pneumococcal infections; Table S2. Unit cost prices; Table
S3. Hospitalization costs of non-IPD-CAP subject stratified by age- and
risk-category in 2012 €.
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